263 related articles for article (PubMed ID: 28750809)
1. Assessing Allosteric Modulation of CB
Scott CE; Kendall DA
Methods Enzymol; 2017; 593():317-342. PubMed ID: 28750809
[TBL] [Abstract][Full Text] [Related]
2. Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate
Jagla CAD; Scott CE; Tang Y; Qiao C; Mateo-Semidey GE; Yudowski GA; Lu D; Kendall DA
Mol Pharmacol; 2019 Jan; 95(1):1-10. PubMed ID: 30322873
[TBL] [Abstract][Full Text] [Related]
3. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
Ahn KH; Mahmoud MM; Kendall DA
J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625
[TBL] [Abstract][Full Text] [Related]
4. Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1).
Ahn KH; Mahmoud MM; Shim JY; Kendall DA
J Biol Chem; 2013 Apr; 288(14):9790-9800. PubMed ID: 23449980
[TBL] [Abstract][Full Text] [Related]
5. Translational potential of allosteric modulators targeting the cannabinoid CB
Lu D; Immadi SS; Wu Z; Kendall DA
Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554
[TBL] [Abstract][Full Text] [Related]
6. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
[TBL] [Abstract][Full Text] [Related]
7. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
[TBL] [Abstract][Full Text] [Related]
8. CB1 Cannabinoid Receptor Signaling and Biased Signaling.
Leo LM; Abood ME
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500853
[TBL] [Abstract][Full Text] [Related]
9. Allosteric modulators restore orthosteric agonist binding to mutated CB
Dopart R; Kendall DA
J Pharm Pharmacol; 2020 Jan; 72(1):84-91. PubMed ID: 31722122
[TBL] [Abstract][Full Text] [Related]
10. Enantiomer-specific positive allosteric modulation of CB
Mitjavila J; Yin D; Kulkarni PM; Zanato C; Thakur GA; Ross R; Greig I; Mackie K; Straiker A
Pharmacol Res; 2018 Mar; 129():475-481. PubMed ID: 29158048
[TBL] [Abstract][Full Text] [Related]
11. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
Baillie GL; Horswill JG; Anavi-Goffer S; Reggio PH; Bolognini D; Abood ME; McAllister S; Strange PG; Stephens GJ; Pertwee RG; Ross RA
Mol Pharmacol; 2013 Feb; 83(2):322-38. PubMed ID: 23160940
[TBL] [Abstract][Full Text] [Related]
12. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
Cawston EE; Redmond WJ; Breen CM; Grimsey NL; Connor M; Glass M
Br J Pharmacol; 2013 Oct; 170(4):893-907. PubMed ID: 23937487
[TBL] [Abstract][Full Text] [Related]
13. Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.
Shen S; Wu C; Lin G; Yang X; Zhou Y; Zhao C; Miao Z; Tian X; Wang K; Yang Z; Liu Z; Guo N; Li Y; Xia A; Zhou P; Liu J; Yan W; Ke B; Yang S; Shao Z
Proc Natl Acad Sci U S A; 2024 Jun; 121(24):e2321532121. PubMed ID: 38830102
[No Abstract] [Full Text] [Related]
14. Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.
Dopart R; Lu D; Lichtman AH; Kendall DA
Drug Metab Rev; 2018 Feb; 50(1):3-13. PubMed ID: 29355030
[TBL] [Abstract][Full Text] [Related]
15. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
Nguyen T; Li JX; Thomas BF; Wiley JL; Kenakin TP; Zhang Y
Med Res Rev; 2017 May; 37(3):441-474. PubMed ID: 27879006
[TBL] [Abstract][Full Text] [Related]
16. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
17. A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid (CB
Yang L; Zhu X; Finlay DB; Green H; Glass M; Duffull SB
Br J Pharmacol; 2023 Oct; 180(20):2661-2676. PubMed ID: 37277184
[TBL] [Abstract][Full Text] [Related]
18. CB
Trexler KR; Eckard ML; Kinsey SG
Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study.
Chung H; Fierro A; Pessoa-Mahana CD
PLoS One; 2019; 14(7):e0220025. PubMed ID: 31335889
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
Manning JJ; Green HM; Glass M; Finlay DB
Neuropharmacology; 2021 Aug; 193():108611. PubMed ID: 34000272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
